Genmab — April 2025

[bibob]

Er der nogen der har adgang til ØUs artikel fra 18/4. https://ugebrev.dk/formue/genmab-laserskarpt-fokus-trods-tilbageslag/

[E_L]

the Rinatabart Sesutecan Ph1/2 adds an endometrial cancer cohort, 100+ extra patients https://clinicaltrials.gov/study/NCT05579366?tab=history&a=23&b=24&compareMode=sideBySide#version-content-panel

[E_L]

as a reminder, we will get data on endometrial cancer in the first half of this year at a major cancer conference

[Anders_]

E L 15:35 Do you know what date the conference is?

[E_L]

no, not yet Anders

[JKY_VH]

Fra MW "Genmab har fået løftet kursmålet for sin amerikanske notering til 29 dollar fra 27 dollar hos den amerikanske investeringsbank Leerink Partners.

Det viser data fra Bloomberg News.

Anbefalingen er stadig "outperform".

Der går ti af Genmabs ADR-aktier på én dansk. Det nye kursmål svarer således til 1877,90 kr."

[ProinvestorNEWS]

Transactions in Connection with Share Buy-back Program https://proinvestor.com/investornyt/1306225/transactions-in-connection-with-share-buy-back-program

[ProinvestorNEWS]

Amerikansk politik presser biotekaktierne https://proinvestor.com/investornyt/1306176/amerikansk-politik-presser-biotekaktierne

[E_L]

https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-22-25-april-2025_en.pdf Teprotumumab
on EMA CHMP agenda

[E_L]

more for the academics i guess, as it has been terminated - DuoHexaBody-CD37 induces direct cytotoxic signaling in diffuse large B-cell lymphoma https://elifesciences.org/reviewed-preprints/106425#x1684353369

[E_L]

ASCO titles released.

[E_L]

ASCO25 Rinatabart sesutecan (Rina-S) for patients with advanced endometrial cancer: First disclosure from dose expansion cohort B2 of the GTC1184-01 study.

Abstract: 3039

| Poster Bd #: 354

[E_L]

ASCO25 A phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) vs investigator’s choice (IC) of chemotherapy in patients with platinum-resistant ovarian cancer (PROC).

Abstract: TPS5627

| Poster Bd #: 520b

[E_L]

ASCO25 New Drugs in Oncology: Incorporation Into Practice - Presentation 2 -

Epcoritamab for Relapsed or Refractory Follicular Lymphoma

[E_L]

ASCO25 Novel analysis of 3-y results from the pivotal EPCORE NHL-1 study: Outcomes in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) and complete response (CR) at 2 y with epcoritamab (epcor) monotherapy.

Abstract: 7043

| Poster Bd #: 226

[Solsen]

Thanks EL. Very interesting abstracts.

[E_L]

one more -
ASCO25 First data from phase 1b/2 EPCORE NHL-4: Epcoritamab (Epcor) in Chinese patients (Pts) with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

Abstract: e19001

[bibob]

God morgen.

[bibob]

[E_L]

Roche Ocrevus sales Q1 25 CHF 1778mn, Columvi 60m, Lunsumio 21m ( via https://www.roche.com/investors )